Nile Therapeutics, Inc.

Nile Therapeutics is a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular disease and other areas of unmet medical need.

CD-NP is a novel rationally designed chimeric natriuretic peptide in clinical studies for an initial indication of acute decompensated heart failure. » More

2NTX-99 is a small molecule with anti-atherothrombotic and nitric oxide donating properties that is in pre-clinical development. » More

December 9, 2008 - Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure » Read
November 13, 2008 - Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results » Read
November 3, 2008 - Nile Therapeutics to Present at Two Upcoming Investor Conferences » Read
October 14, 2008 - Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure » Read

Details on upcoming events are not yet available. Please click here for past events.

Interested investors or potential investors may conveniently receive E-mail alert messages whenever certain new company information is posted to this site. To automatically receive Nile Therapeutics, Inc. e-mail alerts, enter your e-mail address and click on the Subscribe button.